Allison Brashear

Neuroscience PhD at Wake Forest University at Wake Forest University


Wake Forest University Graduate School » Neuroscience PhD at Wake Forest University » People » Allison Brashear

Allison Brashear

Allison Brashear
  • E-mail:
  • Department: Neurology
  • Phone Number: (336) 716-3545
  • Research Interests: Neurosciences/Behavior

Allison Brashear, MD is Professor and Chair of Neurology at Wake Forest University School of Medicine in Winston Salem, NC.

Dr. Brashear has been the principal investigator in many multi-center trials in the treatment of cervical dystonia and spasticity with botulinum toxin. She is the chair of the American Academy of Neurology Spasticity/Dystonia Advisory Board and has directed national courses designed to teach the technique of botulinum toxin treatment.

Dr Brashear is the principal clinician to describe a unique genetic form of dystonia-parkinsonism, Rapid-Onset Dystonia-Parkinsonism (RDP). The gene responsible for RDP, mutations in the Na/K ATPase ?3 subunit, was reported in Neuron in July 2004 and Brain in February 2007.

Dr Brashear’s work has appeared in such journals as The New England Journal of Medicine, Brain, Annals of Neurology, Neurology, Movement Disorders, Muscle and Nerve and others. Dr Brashear is a frequent reviewer for these and other journals. Dr Brashear is the past president of the Indiana Neurological Society. Dr. Brashear is a fellow of the American Academy of Neurology, the American Neurological Association, the American Association of Electrodiagnostic Medicine, and the Movement Disorder Society.

Dr. Brashear graduated from Indiana University School of Medicine in 1987 and completed her training in Neurology at Indiana University School of Medicine in 1991.

 

Brashear A, Hill DF, Snively B, Sweadner KJ, Ozelius L. Now triggers in rapid-onset dystonia-Parkinsonism (RDP) [abstract]. Neurology. 2010; 74(9 Suppl 2):A205.

Brashear A, Hill D, Snively BM, Sweadner KJ, Ozelius L. De novo and recurrent mutations in ATP1A3 are common in rapid-onset dystonia-Parkinsonism [abstract]. Neurology. 2010; 74(9 Suppl 2):A204.

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010; 16(5):316-323.

Yablon SA, Simpson D, Gracies JM, Barbano R, Brashear A. Tizanidine improves geriatric depression scale scores in stroke and brain injury survivors with spastic hemiparesis: post-hoc analysis from a randomized, double-blind, placebo-controlled trial [abstract]. Neurology. 2010; 74(9 Suppl 2):A409-A410.

Brashear A. Botulinum toxin type A: exploring new indications. Drugs Today (Barc). 2010; 46(9):671-682.

Sacino A, Hampton TG, Lingrel JB, Brashear A, Sweadner KJ. Rapid onset dystonia-parkinsonism: symptoms in a mouse deficient in Na,K-ATPase alpha3 [abstract]. Mov Disord. 2009; 24(Suppl 1):S112-S113.

Brashear A, Lambeth K. Spasticity. Curr Treat Options Neurol. 2009; 11(3):153-161.

Barbano RL, Ozelius L, Hill DF, Brashear A. Variable phenotypic expression of rapid onset dystonia parkinsonism in a newly discovered Italian family with a T613M mutation in the ATP1A3 gene [abstract]. In: Abstracts of the 61st Annual Meeting of the American Academy of Neurology; 2009 April 25 – May 2; Seattle (WA). 2009; ():IN2-1.003.

Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009; 3():1-7.

Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009; 80(4):380-385.

Gracies J-M, Yablon S, Raghavan P, Barbano R, Brashear A, Simpson D. Relationship between active function and tone in a placebo-controlled study of botulinum neurotoxin vs tizanidine in upper limb spasticity [abstract]. Arch Phys Med Rehabil. 2009; 90(10):e5-e6.

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70(19):1699-1706.

Brashear A. Clinical comparisons of botulinum neurotoxin formulations. Neurologist. 2008; 14(5):289-298.

Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008; 89(5):799-806.

Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJM, Gollamudi S, Green A, Guimaraes J, Haake B, Klein C, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain. 2007; 130(Pt 3):828-835.

Yablon SA, Brashear A, Gordon MF, Elovic DP, Turkel CC, Daggett S, Liu J, Brin MF. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007; 29(4):683-690.

Brashear A, Farmer D, Wood F, Bressman SB, Dobyns WB, Ozelius LO. ATP1A3 mutations in rapid-onset dystonia Parkinsonism: is there more to the story? [abstract]. Ann Neurol. 2006; 60(Suppl 10):S11.

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006; 67(12):2233-2235.